WO2004035092A3 - Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases - Google Patents

Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases Download PDF

Info

Publication number
WO2004035092A3
WO2004035092A3 PCT/GB2003/004450 GB0304450W WO2004035092A3 WO 2004035092 A3 WO2004035092 A3 WO 2004035092A3 GB 0304450 W GB0304450 W GB 0304450W WO 2004035092 A3 WO2004035092 A3 WO 2004035092A3
Authority
WO
WIPO (PCT)
Prior art keywords
cofilin
inflammatory diseases
activity
treatment
expresion
Prior art date
Application number
PCT/GB2003/004450
Other languages
French (fr)
Other versions
WO2004035092A2 (en
Inventor
Kevin B Bacon
Herath Mudiyanselage At Herath
Ningshu Liu
Christian Rohlff
Original Assignee
Oxford Glycosciences Uk Ltd
Bayer Healthcare Ag
Kevin B Bacon
Herath Mudiyanselage At Herath
Ningshu Liu
Christian Rohlff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences Uk Ltd, Bayer Healthcare Ag, Kevin B Bacon, Herath Mudiyanselage At Herath, Ningshu Liu, Christian Rohlff filed Critical Oxford Glycosciences Uk Ltd
Priority to AU2003271954A priority Critical patent/AU2003271954A1/en
Publication of WO2004035092A2 publication Critical patent/WO2004035092A2/en
Publication of WO2004035092A3 publication Critical patent/WO2004035092A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Methods for the treatment of inflammatory diseases including respiratory diseases, such as asthma and asthma related conditions, comprising regulation of the polypeptide cofilin, agents which modulate the expression or activity of the polypeptide, methods for the identification of such agents and the use of cofilin in the diagnosis of inflammatory diseases including respiratory diseases such as asthma and asthma related conditions.
PCT/GB2003/004450 2002-10-15 2003-10-15 Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases WO2004035092A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003271954A AU2003271954A1 (en) 2002-10-15 2003-10-15 Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0224014.1 2002-10-15
GBGB0224014.1A GB0224014D0 (en) 2002-10-15 2002-10-15 A protein involved in therapy

Publications (2)

Publication Number Publication Date
WO2004035092A2 WO2004035092A2 (en) 2004-04-29
WO2004035092A3 true WO2004035092A3 (en) 2004-06-10

Family

ID=9945978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/004450 WO2004035092A2 (en) 2002-10-15 2003-10-15 Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases

Country Status (3)

Country Link
AU (1) AU2003271954A1 (en)
GB (1) GB0224014D0 (en)
WO (1) WO2004035092A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2321819T3 (en) * 2001-12-28 2009-06-12 Asubio Pharma Co., Ltd. PROMOTERS OF THE GROWTH AND / OR DIFFERENTIATION OF HEMATOPOYETIC MOTHER CELLS AND / OR HEMATOPOYETIC PROGENITORS.
KR101541206B1 (en) * 2007-09-11 2015-08-03 캔서 프리벤션 앤 큐어, 리미티드 Identification of proteins in human serum indicative of pathologies of human lung tissues

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821960A1 (en) * 1996-07-31 1998-02-04 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
EP0821952A1 (en) * 1996-07-31 1998-02-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonic acid amide derivatives for the modulation of apoptosis
WO2002042451A2 (en) * 2000-11-27 2002-05-30 Cytokinetics Aspergillus fumigatus cofilin
WO2002102846A2 (en) * 2001-06-18 2002-12-27 Bioalliance Pharma Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821960A1 (en) * 1996-07-31 1998-02-04 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
EP0821952A1 (en) * 1996-07-31 1998-02-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonic acid amide derivatives for the modulation of apoptosis
WO2002042451A2 (en) * 2000-11-27 2002-05-30 Cytokinetics Aspergillus fumigatus cofilin
WO2002102846A2 (en) * 2001-06-18 2002-12-27 Bioalliance Pharma Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMBACH A ET AL: "The serine phosphatases PP1 and PP2A associate with and activate the actin-binding protein cofilin in human T lymphocytes", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 30, no. 12, December 2000 (2000-12-01), pages 3422 - 3431, XP002222451, ISSN: 0014-2980 *
YONEZAWA N ET AL: "INHIBITION OF THE INTERACTIONS OF COFILIN DESTRIN AND DNASE I WITH ACTIN BY PHOSPHOINOSITIDES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 265, no. 15, 25 May 1990 (1990-05-25), pages 8382 - 8386, XP002194596, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2003271954A1 (en) 2004-05-04
GB0224014D0 (en) 2002-11-27
AU2003271954A8 (en) 2004-05-04
WO2004035092A2 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
WO2005078124A3 (en) Diagnostic marker for cancer
WO2006121610A3 (en) Personal care compositions and methods for their use
WO2002073342A3 (en) Predicting human cognitive performance_____
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2006092668A3 (en) Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
WO2004030585A3 (en) User interface for medical device
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
WO2005030083A3 (en) Methods and products which utilize n-acyl-l-aspartic acid
WO2004076639A3 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
WO2006114105A3 (en) Use of modified factor vii for treating bleeding
AU6471500A (en) Aqueous nasal formulation
WO2005072277A3 (en) Amidated parathyroid hormone fragments and uses thereof
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
MXPA05008704A (en) Fusion proteins of interferon alpha muteins with improved properties.
SE0102147D0 (en) New methods
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
WO2004053120A3 (en) Regulatory elements in the 5' region of the vr1 gene
NO20060781L (en) Use of soluble CD164 in inflammatory and / or autoimmune disorders
WO2004035092A3 (en) Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
WO2004034062A3 (en) Use of cap-1 for the therapy of asthma
DE60214207D1 (en) NAIL POLISH CONTAINING TAZAROTES AND USE THEREOF FOR THE TREATMENT AND / OR THE PREVENTION OF PSORIASIS
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP